Phase 2 clinical trial results show Puma Biotech's (PBYI +1.9%) cancer drug is more effective than Roche's (RHHBY -0.7%) in HER2 breast cancer patients when given before surgery.
In the 193-patient trial, 39% of HER2 patients given the combination of neratinib and chemotherapy achieved a pathologic complete response compared to 23% who received Herceptin and chemo.
Puma's drug is a pill whereas Roche's is given by infusion.